Atea dumps dengue drug as 'unevaluable' endpoint causes timelines, forecast costs to spiral

Clinical data have convinced Atea Pharmaceuticals it cannot make the numbers add up in dengue fever. Based on the results, the antiviral biotech calculates it would take at least three years and cost several hundred million dollars to run phase 2 studies, prompting it to put the program on the back burner.